Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease

Thorax

Volumn 70, Issue 10, 2015, Pages 984-989

  Antoni, Torres ^a   Blasi, Francesco ^b   Dartois, Nathalie ^c   Akova, Murat ^d  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY OF MILAN   (Italy)

^c PFIZER INC   (United States)

^d HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; PNEUMOCOCCUS VACCINE;

AGE; ARTICLE; ASTHMA; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE EXACERBATION; EUROPE; HEALTH CARE COST; HEART DISEASE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INHALER; ISCHEMIC HEART DISEASE; MORTALITY; PASSIVE SMOKING; PNEUMOCOCCAL INFECTION; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SMOKING; STREPTOCOCCUS PNEUMONIA; UNITED STATES; ADVERSE EFFECTS; COMMUNITY ACQUIRED INFECTION; COMPLICATION; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE;

ASTHMA; CHRONIC DISEASE; COMMUNITY-ACQUIRED INFECTIONS; DIABETES COMPLICATIONS; HEART DISEASES; HUMANS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SMOKING; STREPTOCOCCUS PNEUMONIAE;

EID: 84942087848     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2015-206780     Document Type: Article

References (75)

1. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012;67:71-9.
2. Ludwig E, Unal S, Bogdan M, et al. Opportunity for healthy ageing: lessening the burden of adult pneumococcal disease in Central and Eastern Europe, and Israel. Cent Eur J Public Health 2012;20:121-5.
3. Torne AN, Dias JG, Quinten C, et al. European enhanced surveillance of invasive pneumococcal disease in 2010: data from 26 European countries in the post-heptavalent conjugate vaccine era. Vaccine 2014;32:3644-50.
4. File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010;122:130-41.
5. Nicoli EJ, Trotter CL, Turner KM, et al. Influenza and RSV make a modest contribution to invasive pneumococcal disease incidence in the UK. J Infect 2013;66:512-20.
6. Torres A, Peetermans WE, Viegi G, et al. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax 2013;68:1057-65.
7. Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis 2014;1:ofu024.
8. Vinogradova Y, Hippisley-Cox J, Coupland C. Identification of new risk factors for pneumonia: population-based case-control study. Br J Gen Pract 2009;59:e329-38.
9. Cilloniz C, Polverino E, Ewig S, et al. Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. Chest 2013;144:999-1007.
10. Mor A, Thomsen RW, Ulrichsen SP, et al. Chronic heart failure and risk of hospitalization with pneumonia: a population-based study. Eur J Intern Med 2013;24:349-53.
11. Nyboe C, Olsen MS, Nielsen-Kudsk JE, et al. Risk of pneumonia in adults with closed versus unclosed atrial septal defect (from a nationwide cohort study). Am J Cardiol 2014;114:105-10.
12. van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012;65:17-24.
13. Inghammar M, Engstrom G, Kahlmeter G, et al. Invasive pneumococcal disease in patients with an underlying pulmonary disorder. Clin Microbiol Infect 2013;19:1148-54.
14. Seminog OO, Goldacre MJ. Risk of pneumonia and pneumococcal disease in people hospitalized with diabetes mellitus: English record-linkage studies. Diabet Med 2013;30:1412-19.
15. Juthani-Mehta M, De RN, Allore H, et al. Modifiable risk factors for pneumonia requiring hospitalization of community-dwelling older adults: the Health, Aging, and Body Composition Study. J Am Geriatr Soc 2013;61:1111-18.
16. Almirall J, Bolibar I, Serra-Prat M, et al. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J 2008;31:1274-84.
17. Garcia-Vidal C, Carratala J, Fernandez-Sabe N, et al. Aetiology of, and risk factors for, recurrent community-acquired pneumonia. Clin Microbiol Infect 2009;15:1033-8.
18. Gau JT, Acharya U, Khan S, et al. Pharmacotherapy and the risk for community-acquired pneumonia. BMC Geriatr 2010;10:45.
19. Jackson ML, Nelson JC, Jackson LA. Risk factors for community-acquired pneumonia in immunocompetent seniors. J Am Geriatr Soc 2009;57:882-8.
20. Loeb M, Neupane B, Walter SD, et al. Environmental risk factors for community-acquired pneumonia hospitalization in older adults. J Am Geriatr Soc 2009;57:1036-40.
21. Mullerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med 2012;106:1124-33.
22. Obiora E, Hubbard R, Sanders RD, et al. The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort. Thorax 2013;68:163-70.
23. Rodriguez LA, Ruigomez A, Wallander MA, et al. Acid-suppressive drugs and community-acquired pneumonia. Epidemiology 2009;20:800-6.
24. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, et al. Epidemiology of community-acquired pneumonia in older adults: a population-based study. Respir Med 2009;103:309-16.
25. Flory JH, Joffe M, Fishman NO, et al. Socioeconomic risk factors for bacteraemic pneumococcal pneumonia in adults. Epidemiol Infect 2009;137:717-26.
26. Watt JP, O'Brien KL, Benin AL, et al. Risk factors for invasive pneumococcal disease among Navajo adults. Am J Epidemiol 2007;166:1080-7.
27. Almirall J, Bolibar I, Serra-Prat M, et al. Inhaled drugs as risk factors for community-acquired pneumonia. Eur Respir J 2010;36:1080-7.
28. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;3:CD010115.
29. Almirall J, Serra-Prat M, Bolibar I, et al. Passive smoking at home is a risk factor for community-acquired pneumonia in older adults: a population-based case-control study. BMJ Open 2014;4:e005133.
30. Jacups SP, Cheng A. The epidemiology of community acquired bacteremic pneumonia, due to Streptococcus pneumoniae, in the top end of the Northern Territory, Australia-over 22 years. Vaccine 2011;29:5386-92.
31. Ehrlich SF, Quesenberry CPJ, Van Den Eeden SK, et al. Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care 2010;33:55-60.
32. Kornum JB, Thomsen RW, Riis A, et al. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care 2008;31:1541-5.
33. Skull SA, Andrews RM, Byrnes GB, et al. Hospitalized community-acquired pneumonia in the elderly: an Australian case-cohort study. Epidemiol Infect 2009;137:194-202.
34. Wotton CJ, Goldacre MJ. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. J Epidemiol Community Health 2012;66:1177-81.
35. Peleg AY, Weerarathna T, McCarthy JS, et al. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev 2007;23:3-13.
36. van den Borst B, Gosker HR, Zeegers MP, et al. Pulmonary function in diabetes: a metaanalysis. Chest 2010;138:393-406.
37. Agborsangaya CB, Ngwakongnwi E, Lahtinen M, et al. Multimorbidity prevalence in the general population: the role of obesity in chronic disease clustering. BMC Public Health 2013;13:1161.
38. Ornstein SM, Nietert PJ, Jenkins RG, et al. The prevalence of chronic diseases and multimorbidity in primary care practice: a PPRNet report. J Am Board Fam Med 2013;26:518-24.
39. Violan C, Foguet-Boreu Q, Hermosilla-Perez E, et al. Comparison of the information provided by electronic health records data and a population health survey to estimate prevalence of selected health conditions and multimorbidity. BMC Public Health 2013;13:251.
40. Ricketson LJ, Nettel-Aguirre A, Vanderkooi OG, et al. Factors influencing early and late mortality in adults with invasive pneumococcal disease in Calgary, Canada: a prospective surveillance study. PLoS ONE 2013;8:e71924.
41. Sicras-Mainar A, Ibanez-Nolla J, Cifuentes I, et al. Retrospective epidemiological study for the characterization of community-acquired pneumonia and pneumococcal pneumonia in adults in a well-defined area of Badalona (Barcelona, Spain). BMC Infect Dis 2012;12:283.
42. Burgos J, Lujan M, Larrosa MN, et al. Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes. Eur Respir J 2014;43:545-53.
43. Corrales-Medina VF, Musher DM, Wells GA, et al. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 2012;125:773-81.
44. Naucler P, Darenberg J, Morfeldt E, et al. Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia. Thorax 2013;68:571-9.
45. Adamuz J, Viasus D, Jimenez-Martinez E, et al. Incidence, timing and risk factors associated with 1-year mortality after hospitalization for community-acquired pneumonia. J Infect 2014;68:534-41.
46. Kothe H, Bauer T, Marre R, et al. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J 2008;32:139-46.
47. Thomsen RW, Kasatpibal N, Riis A, et al. The impact of pre-existing heart failure on pneumonia prognosis: population-based cohort study. J Gen Intern Med 2008;23:1407-13.
48. Molinos L, Clemente MG, Miranda B, et al. Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. J Infect 2009;58:417-24.
49. Loke YK, Kwok CS, Wong JM, et al. Chronic obstructive pulmonary disease and mortality from pneumonia: meta-analysis. Int J Clin Pract 2013;67:477-87.
50. Liapikou A, Polverino E, Ewig S, et al. Severity and outcomes of hospitalised community-acquired pneumonia in COPD patients. Eur Respir J 2012;39:855-61.
51. Sellares J, Lopez-Giraldo A, Lucena C, et al. Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia. Am J Respir Crit Care Med 2013;187:1241-8.
52. Sibila O, Mortensen EM, Anzueto A, et al. Prior cardiovascular disease increases long-term mortality in COPD patients with pneumonia. Eur Respir J 2014;43:36-42.
53. Bello S, Menendez R, Torres A, et al. Tobacco smoking increases the risk for death from pneumococcal pneumonia. Chest 2014;146:1029-37.
54. Kang CI, Song JH, Kim SH, et al. Risk factors and pathogenic significance of bacteremic pneumonia in adult patients with community-acquired pneumococcal pneumonia. J Infect 2013;66:34-40.
55. Hak E, Bont J, Hoes AW, et al. Prognostic factors for serious morbidity and mortality from community-acquired lower respiratory tract infections among the elderly in primary care. Fam Pract 2005;22:375-80.
56. Verhaegen J, Flamaing J, De BW, et al. Epidemiology and outcome of invasive pneumococcal disease among adults in Belgium, 2009-2011. Euro Surveill 2014;19:14-22.
57. Wyrwich KW, Yu H, Sato R, et al. Community-acquired pneumonia: symptoms and burden of illness at diagnosis among US adults aged 50 years and older. Patient 2013;6:125-34.
58. Roca B, Almagro P, Lopez F, et al. Factors associated with mortality in patients with exacerbation of chronic obstructive pulmonary disease hospitalized in general medicine departments. Intern Emerg Med 2011;6:47-54.
59. Myint PK, Lowe D, Stone RA, et al. UK National COPD Resources and Outcomes Project 2008: patients with chronic obstructive pulmonary disease exacerbations who present with radiological pneumonia have worse outcome compared to those with non-pneumonic chronic obstructive pulmonary disease exacerbations. Respiration 2011;82:320-7.
60. Yende S, D'Angelo G, Kellum JA, et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008;177:1242-7.
61. Yende S, van der Poll T, Lee M, et al. The influence of pre-existing diabetes mellitus on the host immune response and outcome of pneumonia: analysis of two multicentre cohort studies. Thorax 2010;65:870-7.
62. Musher DM, Rueda AM, Kaka AS, et al. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 2007;45:158-65.
63. Mortensen EM, Metersky ML. Long-term mortality after pneumonia. Semin Respir Crit Care Med 2012;33:319-24.
64. Pletz MW, von BH, van der Linden M, et al. The burden of pneumococcal pneumonia-experience of the German competence network CAPNETZ. Pneumologie 2012;66:470-5.
65. De Graeve D, Beutels P. Economic aspects of pneumococcal pneumonia: a review of the literature. Pharmacoeconomics 2004;22:719-40.
66. Sato R, Gomez RG, Nelson S, et al. Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged >/=50 years. Appl Health Econ Health Policy 2013;11:251-8.
67. Yu H, Rubin J, Dunning S, et al. Clinical and economic burden of community-acquired pneumonia in the Medicare fee-for-service population. J Am Geriatr Soc 2012;60:2137-43.
68. Tichopad A, Roberts C, Gembula I, et al. Clinical and economic burden of community-acquired pneumonia among adults in the Czech Republic, Hungary, Poland and Slovakia. PLoS ONE 2013;8:e71375.
69. Bauer TT, Welte T, Ernen C, et al. Cost analyses of community-acquired pneumonia from the hospital perspective. Chest 2005;128:2238-46.
70. Sun HK, Nicolau DP, Kuti JL. Resource utilization of adults admitted to a large urban hospital with community-acquired pneumonia caused by Streptococcus pneumoniae. Chest 2006;130:807-14.
71. Reyes S, Martinez R, Valles JM, et al. Determinants of hospital costs in community-acquired pneumonia. Eur Respir J 2008;31:1061-7.
72. Suter-Widmer I, Christ-Crain M, Zimmerli W, et al. Predictors for length of hospital stay in patients with community-acquired pneumonia: results from a Swiss multicenter study. BMC Pulm Med 2012;12:21.
73. Bartolome M, Almirall J, Morera J, et al. A population-based study of the costs of care for community-acquired pneumonia. Eur Respir J 2004;23:610-16.
74. Kleinman NL, Yu H, Beren IA, et al. Work-related and health care cost burden of community-acquired pneumonia in an employed population. J Occup Environ Med 2013;55:1149-56.
75. Fry AM, Shay DK, Holman RC, et al. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA 2005;294:2712-19.